Binnenwerk 57 1 Rechterpagina (oneven paginanummers 3 mm weggesneden Veilige zone 8 mm 5 mm weggesneden despite the large number of RCTs that have evaluated adjuvant treatment effectiveness in colon cancer patients, the effectiveness in the stage II population remains unclear, mainly due to insufficient power in the studies for the stage II population. Furthermore, over the years the number of examined regional lymphnodes per patients increased as this provides important information about the patients’ prognosis, which resulted in a migration of disease stage.9 That is, a patient that was classified as stage II before the increasing number of evaluated lymphnodes, could possibly be classified as stage III in a more recently conducted study. Secondly, there is no consensus on which high-risk features should be taken into account to select stage II colon cancer patients for adjuvant chemotherapy. Thirdly, there is less convincing data for the optimal duration of adjuvant treatment in stage II colon cancer patients compared to stage III colon cancer. Moreover, when deliberating on the optimal treatment choice in stage II colon cancer, it is important to explicitly take into account the fact that there are also health risks associated with adjuvant chemotherapy. To guide the clinical decision making process, the potential health gain of adjuvant treatment should be carefully balanced against the potential harms. Summarizing, the identification of patients that require adjuvant chemotherapy as well as the optimal treatment duration remains challenging. Below the three knowledge gaps are discussed in more detail. The effect of adjuvant chemotherapy in stage II colon cancer The treatment effect of adjuvant chemotherapy in stage II colon cancer has been evaluated in several randomized clinical trials (RCTs) during the last decades. IMPACT was the first collaboration that conducted a pooled analysis of 1,016 patients with stage II colon cancer from 5 RCTs, which compared a fluorouracil-leucovorin (FU-LV) treated group to a control group. The group that was treated with FU-LV demonstrated a small, statistically non-significant improvement in 5-year DFS and OS. The DFS rates were 76% versus 73% and the OS rates were 82% versus 80% for the FU-LV group compared to the control group, respectively.10 Subsequently, in 2004 another meta-analysis was conducted in which 3,302 patients were included with stage II or III colon cancer from 7 RCTs (the 5 RCTs included in IMPACT and two additional RCTs), which compared FU-LV to a control group. In a stage II colon cancer subgroup analysis (n=1,440), a small but significant difference of 4% (76% versus 72%, p=0.049) was found for DFS and a small non-significant difference of 1% in OS (81% versus 80%, p=0.113).11 In 2007, results of the QUASAR trial became available. In the QUASAR trial, 3,239 resected stage I (1%), II (91%) and III (8%) patients were included of which 71% was diagnosed with colon cancer and 29% with rectal cancer. Patients were randomized to a FU-LV arm (with or without levamisole) or a control arm. The QUASAR trial demonstrated a relative risk of recurrence of 0.78 (95% CI, 0.67-0.91) and a relative risk of OS of 0.82 (95% CI, 0.70-0.95) for FU-LV treated patients compared to observation. The authors reported an improvement in OS of 3.6% for FU-LV compared to observation within 5-year follow-up, which was assessed as having limited clinical impact.5 After the QUASAR trial, the MOSAIC and NSABP-07 trials were conducted to evaluate the benefit of the addition of oxaliplatin to FU-LV (FOLFOX) in stage II and III colon cancer. In the secondary analysis of stage II colon cancer patients only (n=899), the MOSAIC trial reported a statistically non-significant improvement in DFS with a hazard ratio (HR) of 0.84 (95%CI: 0.62-1.14) for FOLFOX compared to FU-LV. However, the HR for OS was 1 (95% CI: 0.70-1.41), indicating equal survival probabilities in both groups.12 In the NSABP C-07 trial, 2,409 patients (29% stage II and 71% stage III) were included. In a separate stage II analysis (n=695), HRs of 0.94 (95% CI: 0.70-1.26) and 1.04 (95%: 0.72-1.50) for DFS and OS, respectively, were found when comparing FOLFOX to FU-LV.13 1 9 General introduction 149602 Jongeneel BNW.indd 9 04-06-2021 13:47 Witmarge 23 mm Documentformaat 17,6 x 25 cm (B5) Eindformaat na snijden 17 x 24 cm Veiligheidsmarge 8 mm Ruimte voor tekst en tabellen o stage III colon cancer. Moreover, when deliberating on the optimal treatment choice in on cancer, it is important to explicitly take into account the fact that there are also health ated with adjuvant chemotherapy. To guide the clinical decision making process, the ealth gain of adjuvant treatment should be carefully balanced against the potential harms. g, the identification of patients that require adjuvant chemotherapy as well as the optimal duration remains challenging. Below the three knowledge gaps are discussed in more detail. f adjuvant chemotherapy in stage II colon cancer ent effect of adjuvant chemotherapy in stage II colon cancer has been evaluated in several d clinical trials (RCTs) during the last decades. IMPACT was the first collaboration that a pooled analysis of 1,016 patients with stage II colon cancer from 5 RCTs, which compared cil-leucovorin (FU-LV) treated group to a control group. The group that was treated with onstrated a small, statistically non-significant improvement in 5-year DFS and OS. The DFS 76% versus 73% and the OS rates were 82% versus 80% for the FU-LV group compared to group, respectively.10 Subsequently, in 2004 another meta-analysis was conducted in which nts were included with stage II or III colon cancer from 7 RCTs (the 5 RCTs included in d two additional RCTs), which compared FU-LV to a control group. In a stage II colon cancer nalysis (n=1,440), a small but significant difference of 4% (76% versus 72%, p=0.049) was FS and a small non-significant difference of 1% in OS (81% versus 80%, p=0.113).11 ults of the QUASAR trial became available. In the QUASAR trial, 3,239 resected stage I (1%), d III (8%) patients were included of which 71% was diagnosed with colon cancer and 29% cancer. Patients were randomized to a FU-LV arm (with or without levamisole) or a control UASAR trial demonstrated a relative risk of recurrence of 0.78 (95% CI, 0.67-0.91) and a of OS of 0.82 (95% CI, 0.70-0.95) for FU-LV treated patients compared to observation. The orted an improvement in OS of 3.6% for FU-LV compared to observation within 5-year which was assessed as having limited clinical impact.5 After the QUASAR trial, the MOSAIC -07 trials were conducted to evaluate the benefit of the addition of oxaliplatin to FU-LV stage II and III colon cancer. In the secondary analysis of stage II colon cancer patients only e MOSAIC trial reported a statistically non-significant improvement in DFS with a hazard f 0.84 (95%CI: 0.62-1.14) for FOLFOX compared to FU-LV. However, the HR for OS was 1 70-1.41), indicating equal survival probabilities in both groups.12 In the NSABP C-07 trial, nts (29% stage II and 71% stage III) were included. In a separate stage II analysis (n=695), (95% CI: 0.70-1.26) and 1.04 (95%: 0.72-1.50) for DFS and OS, respectively, were found aring FOLFOX to FU-LV.13 9 04-06-2021 13:47 Witmarge 25 mm
RkJQdWJsaXNoZXIy MTk4NDMw